Eli Lilly's (LLY -0.1%) once-weekly type 2 diabetes drug, the investigational glucagon-like peptide (GLP-1) receptor agonist dulaglutide, demonstrates superior reductions in HbA1c compared to insulin glargine with a lower risk of hypoglycemia.
In the Award-2 Phase 3 clinical trial evaluating the safety and efficacy of once-weekly dulaglutide compared to insulin glargine as an add-on to combination therapy with sulfonylurea and metformin, dulaglutide showed superior glucose control at 52 and 78 weeks. Also, significantly more dulaglutide-treated patients achieved HbA1c levels of <7%.
In the Award-4 Phase 3 trial, once-weekly dulaglutide combined with prandial insulin lispro provided superior glucose control at 26 and 52 weeks compared to the traditional basal/bolus combination of insulin glargine and prandial insulin lispro. At the 26-week primary endpoint, significantly more dulaglutide-treated patients reached HbA1c levels of <7%.
Hypoglycemia rates were lower in the dulaglutide groups in both studies.